Exelixis (EXEL)
(Real Time Quote from BATS)
$20.46 USD
-0.11 (-0.54%)
Updated May 28, 2024 11:26 AM ET
3-Hold of 5 3
B Value C Growth F Momentum C VGM
Brokerage Reports
Exelixis, Inc. [EXEL]
Reports for Purchase
Showing records 61 - 80 ( 178 total )
Company: Exelixis, Inc.
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Exelixis, Inc.
Industry: Medical - Biomedical and Genetics
Exelixis Reports Surprising 3Q21 Cabometyx Revenue Miss, Trimming Estimates, Lowering PT from $65 to $52
Provider: H.C. Wainwright & Co., Inc.
Analyst: KING M
Company: Exelixis, Inc.
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Exelixis, Inc.
Industry: Medical - Biomedical and Genetics
Exelixis Strikes STORM Partnership and In-Licenses XL114 from Aurigene
Provider: H.C. Wainwright & Co., Inc.
Analyst: KING M
Company: Exelixis, Inc.
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Exelixis, Inc.
Industry: Medical - Biomedical and Genetics
Company: Exelixis, Inc.
Industry: Medical - Biomedical and Genetics
ESMO and post-FDA updates on COSMIC-021 Trial Data in mCRPC
Provider: H.C. Wainwright & Co., Inc.
Analyst: KING M
Company: Exelixis, Inc.
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Exelixis, Inc.
Industry: Medical - Biomedical and Genetics
The Best is Yet to Come for Exelixis; Fireside Chat with CEO Michael Morrissey; Reiterate Buy Rating and $65 PT
Provider: H.C. Wainwright & Co., Inc.
Analyst: KING M
Company: Exelixis, Inc.
Industry: Medical - Biomedical and Genetics
Momentum Builds for Exelixis on Japanese Approval and ESMO 2021
Provider: H.C. Wainwright & Co., Inc.
Analyst: KING M
Company: Exelixis, Inc.
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Exelixis, Inc.
Industry: Medical - Biomedical and Genetics
Exelixis and Invenra Expand Collaboration to Include Additional Oncology Antibody Targets
Provider: H.C. Wainwright & Co., Inc.
Analyst: KING M
Company: Exelixis, Inc.
Industry: Medical - Biomedical and Genetics
A Beat and Raise for Exelixis-Still More to Come from Cabozantinib; Raising PT to $64
Provider: H.C. Wainwright & Co., Inc.
Analyst: KING M
Company: Exelixis, Inc.
Industry: Medical - Biomedical and Genetics
Our Prelude to Exelixis 2Q21 Earnings; Reiterate Buy and $35 PT
Provider: H.C. Wainwright & Co., Inc.
Analyst: KING M
Company: Exelixis, Inc.
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Exelixis, Inc.
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Exelixis, Inc.
Industry: Medical - Biomedical and Genetics
Exelixis-COSMIC-312 Disappoints on Overall Survival, Reiterate Buy at a Reduced PT of $35
Provider: H.C. Wainwright & Co., Inc.
Analyst: KING M
Company: Exelixis, Inc.
Industry: Medical - Biomedical and Genetics
CMO Takes Medical Leave of Absence; We See No Change to Fundamentals
Provider: H.C. Wainwright & Co., Inc.
Analyst: KING M
Company: Exelixis, Inc.
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Exelixis, Inc.
Industry: Medical - Biomedical and Genetics
We are initiating coverage of Exelixis with a Buy rating and a price target of $47.
Provider: H.C. Wainwright & Co., Inc.
Analyst: KING M